Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Monoclonal Antibodies Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
5.1.2. Restraints
5.1.2.1. Pricing of therapeutic mAbs are high
5.1.3. Opportunities
5.1.3.1. Substantial increase in the number of approvals per year
5.1.3.2. Improvements in supply chain and distribution network
5.1.4. Challenges
5.1.4.1. Limitation in current manufacturing and purification processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Monoclonal Antibodies Market, by Source Type
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
6.5. Murine

7. Monoclonal Antibodies Market, by Production Type
7.1. Introduction
7.2. In Vitro
7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Infectious Diseases
8.5. Inflammatory Diseases
8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes

10. Americas Monoclonal Antibodies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Monoclonal Antibodies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Monoclonal Antibodies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AbbVie, Inc.
14.1.3. ADC Therapeutics SA
14.1.4. Almac Group Limited
14.1.5. Amgen Inc.
14.1.6. Astellas Pharma Inc.
14.1.7. Biogen Inc.
14.1.8. Bristol Myers Squibb Company
14.1.9. Eli Lilly and Company
14.1.10. F. Hoffmann-La Roche Ltd.
14.1.11. Johnson & Johnson Services, Inc.
14.1.12. Novartis AG
14.1.13. Pfizer Inc.
14.1.14. Sanofi S.A.
14.1.15. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing



List of Figures

FIGURE 1. MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 7. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2030 (%)
FIGURE 8. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2030 (%)
FIGURE 10. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 6. MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 11. MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 14. MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 191. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING